Dr. Laurence Albiges highlights updated data showing that belzutifan plus lenvatinib delivers durable responses and prolonged progression-free survival in heavily pretreated renal cell carcinoma. With over two years of follow-up, the combination demonstrates a strong efficacy signal compared to historical single-agent therapies, alongside a manageable safety profile. She notes that anemia and hypoxia require monitoring but are often manageable, and suggests this regimen could become a key option in the second-line setting.
Belzutifan Moves Earlier in Kidney Cancer Care
Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan
